Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Development of ligand-targeted liposomes for cancer therapy.

Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC.

Expert Opin Ther Targets. 2004 Aug;8(4):335-53. Review.

PMID:
15268628
2.

Ligand-targeted liposomes for cancer treatment.

Sapra P, Tyagi P, Allen TM.

Curr Drug Deliv. 2005 Oct;2(4):369-81. Review.

PMID:
16305440
3.

Future directions of liposome- and immunoliposome-based cancer therapeutics.

Park JW, Benz CC, Martin FJ.

Semin Oncol. 2004 Dec;31(6 Suppl 13):196-205. Review.

PMID:
15717745
4.

Liposome targeting to tumors using vitamin and growth factor receptors.

Drummond DC, Hong K, Park JW, Benz CC, Kirpotin DB.

Vitam Horm. 2000;60:285-332. Review.

PMID:
11037627
5.

Ligand-targeted liposomal therapies of neuroblastoma.

Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, Piccardi F, Cilli M, Allen TM, Ponzoni M.

Curr Med Chem. 2007;14(29):3070-8. Review.

PMID:
18220743
6.

Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer.

Laginha KM, Moase EH, Yu N, Huang A, Allen TM.

J Drug Target. 2008 Aug;16(7):605-10. doi: 10.1080/10611860802229978.

PMID:
18686132
7.

From conventional to stealth liposomes: a new frontier in cancer chemotherapy.

Cattel L, Ceruti M, Dosio F.

Tumori. 2003 May-Jun;89(3):237-49. Review.

PMID:
12908776
8.

Adventures in targeting.

Allen TM, Sapra P, Moase E, Moreira J, Iden D.

J Liposome Res. 2002 Feb-May;12(1-2):5-12.

PMID:
12604033
9.

Tumour-selective drug delivery via folate receptor-targeted liposomes.

Pan X, Lee RJ.

Expert Opin Drug Deliv. 2004 Nov;1(1):7-17. Review.

PMID:
16296717
10.

Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment.

Di Paolo D, Pastorino F, Brignole C, Marimpietri D, Loi M, Ponzoni M, Pagnan G.

Tumori. 2008 Mar-Apr;94(2):246-53.

11.

Ligand-targeted liposomal anticancer drugs.

Sapra P, Allen TM.

Prog Lipid Res. 2003 Sep;42(5):439-62. Review.

PMID:
12814645
12.

Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.

Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ.

Expert Opin Drug Deliv. 2008 Jan;5(1):87-103. Review.

PMID:
18095930
13.

Pros and cons of the liposome platform in cancer drug targeting.

Gabizon AA, Shmeeda H, Zalipsky S.

J Liposome Res. 2006;16(3):175-83. Review.

PMID:
16952872
14.

A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer.

Chang DK, Lin CT, Wu CH, Wu HC.

PLoS One. 2009;4(1):e4171. doi: 10.1371/journal.pone.0004171. Epub 2009 Jan 12.

15.

Targeted cancer therapies in the twenty-first century: lessons from imatinib.

Stegmeier F, Warmuth M, Sellers WR, Dorsch M.

Clin Pharmacol Ther. 2010 May;87(5):543-52. doi: 10.1038/clpt.2009.297. Epub 2010 Mar 17. Review.

PMID:
20237469
16.

Ligand-based targeted therapy for cancer tissue.

Das M, Mohanty C, Sahoo SK.

Expert Opin Drug Deliv. 2009 Mar;6(3):285-304. doi: 10.1517/17425240902780166. Review.

PMID:
19327045
17.

Folate receptor-targeted liposomes as vectors for therapeutic agents.

Gosselin MA, Lee RJ.

Biotechnol Annu Rev. 2002;8:103-31. Review.

PMID:
12436917
18.

Nanoparticles for tumor targeted therapies and their pharmacokinetics.

Wang J, Sui M, Fan W.

Curr Drug Metab. 2010 Feb;11(2):129-41. Review.

PMID:
20359289
19.

Nanoparticles for drug delivery in cancer treatment.

Haley B, Frenkel E.

Urol Oncol. 2008 Jan-Feb;26(1):57-64. doi: 10.1016/j.urolonc.2007.03.015. Review.

PMID:
18190833

Supplemental Content

Support Center